Equity Overview
Price & Market Data
Price: $4.10
Daily Change: -$0.174 / 4.25%
Daily Range: $4.08 - $4.40
Market Cap: $740,093,650
Daily Volume: 2,174,061
Performance Metrics
1 Week: 5.67%
1 Month: 4.59%
3 Months: -0.61%
6 Months: 182.8%
1 Year: 30.99%
YTD: 39.93%
Company Details
Employees: 214
Sector: Health technology
Industry: Biotechnology
Country:
Details
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.